Skip to main content
PolicySpeak
← All files
AG

Attomol GmbH

Company · Germany

not in the EU Transparency RegisterThis organization files on consultations without a register number, so its record here is built from its filings alone. Register facts (staff, costs, accreditations) are not available for it.

2
positions filed
in the 665 files tracked
1
legislative file
of 665 tracked
0
with a full position paper
attached to a submission

Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.

Track Attomol in PolicySpeak: request access →

Follow Attomol GmbH

An email when this organization files on a consultation we publish.

We use your email for these updates, and PolicySpeak may contact you about the product. Unsubscribe in one click. Privacy policy.

Work at Attomol GmbH? so we know who speaks for it.

Their record over time

Attomol GmbH filed 2 positions between 16 Sept 2025 and 6 Oct 2025, across 1 of the 665 legislative files tracked here.

What they argued

Simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and support of the European Medicines Agency for the expert panels on medical devices and the list of Union harmonisation legislationfiled 6 Oct 2025source

Sufficient views were shared on the excessive burden of complying with the IVDR. Here are a few opportunities for improvement: 1. Clear communication about what is allowed, even though it is not specifically formulated in the IVDR. This includes: (a) the non-necessary fulfilment of certain requirements (e.g.

Filed in German · English published by the European Commission

Simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and support of the European Medicines Agency for the expert panels on medical devices and the list of Union harmonisation legislationfiled 16 Sept 2025source

The application of the MDR/IVDR Regulations to existing products, some of which have proved for decades that they do not pose a risk to patients, is incomprehensible. Unnecessary requirements which only serve to complete paper, but do not make the products themselves safer at all. These documents are then subject to exorbitant fees from notified bodies, which are justified by the expertise of their staff.

Filed in German · English published by the European Commission

Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.

Put Attomol GmbH next to another organization. Same files, same register facts, side by side. Compare →

Is this your organization?

Everything on this page comes from Attomol GmbH’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.

Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.